BioNTech SE - ADR

NASDAQ:BNTX   3:59:59 PM EDT
247.69
-2.64 (-1.06%)
Products, Other Pre-Announcement

Biontech Q4 Net Profit At EUR 366.9 Mln

Published: 03/30/2021 10:43 GMT
BioNTech SE - ADR (BNTX) - Biontech Announces Full Year 2020 Financial Results and Corporate Update.
Total Revenues Were Estimated to Be EUR 345.4 Million for Three Months Ended December 31, 2020.
Biontech and Pfizer Expect to Increase Bnt162b2 Manufacturing Capacity to Up to 2.5 Billion Doses by End of 2021.
Net Profit / Loss: Net Profit Was EUR 366.9 Million for Three Months Ended December 31, 2020, Compared to EUR 58.2 Million Net Loss for Three Months Ended December 31, 2019.
For Year Ended December 31, 2020, Total Revenues Were Estimated to Be EUR 482.3 Million, Compared to EUR 108.6 Million for Comparative Prior Year Period.
For Year Ended December 31, 2020, Net Profit Was EUR 15.2 Million, Compared to EUR 179.2 Million Net Loss for Comparative Prior Year Period.
Research and Development Expenses: Research and Development Expenses Were EUR 257.0 Million for Three Months Ended December 31, 2020,.
For Year Ended December 31, 2020, Research and Development Expenses Were EUR 645.0 Million, Compared to EUR 226.5 Million for Comparative Prior Year Period.
Additional Revenues Related to Further Supply Contracts for Deliveries in 2021 Expected.
Full Year 2021 Manufacturing Capacity Target Raised From 2.0 to 2.5 Billion Doses to Be Able to Address Increased Demand.
Planned Full Year 2021 Expenses and Capex (2) Research and Development Expenses EUR 750 Million - EUR 850 Million.